$1.22
+0.05 (+4.27%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GNTA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 1 with posted results
Held by 0 tracked-famous managers · FINRA short interest 1.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMTNCT03866109Tolerability and safety of Temferon over the first 90 days following administration as determined by the incidence of adverse eventsOpen-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: LVLP (pt GBM-01034) took place on 27may2026. The 2 remaining slots allocated by the protocol for the additional cohort to generate safety data prior to study Part B will not be filled. No safety concerns. Benefit-risk profile unchanged. | Drug: Temferon | Glioblastoma Multiforme | 25 | 2026-05-27actual | 2026-06-11 |
| A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell CarcinomaNCT06716853Tolerability and safety of conditioning and Temferon, over the first 90 days following administration, as determined by the incidence of adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Persistent challenges have been encountered in patient recruitment, difficulty in identifying a sufficient number of eligible subjects. The decision to terminate the study was not based on any safety concerns. Benefit-risk profile of IP unchanged. | Genetic: Temferon · Biological: Pembrolizumab · Drug: Cabozantinib | Clear Cell RCC | 10 | 2026-01-23actual | 2026-02-09 |
| A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)NCT03875495results2022-01-28Tolerability and Safety of Temferon Over the First 90 Days Following Administration as Determined by the Incidence of CTCAEsOpen-label · TreatmentStudy Protocol ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Failure to recruit patients | Drug: Temferon | Multiple Myeloma | 9 | 2021-04-02actual | 2022-01-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19